GABARAP deficiency modulates expression of NaPi-IIa in renal brush-border membranes
Sonja C. Reining(University of Zurich), Nati Hernando(University of Zurich), Serge M. Gisler(University of Zurich), Heinrich Betz(Max Planck Institute for Medical Research), Gregory A. O’Sullivan(Max Planck Institute of Molecular Cell Biology and Genetics), Daniel G. Fuster(University of Bern), Heini Murer, Jürg Biber, Orson W. Moe(Io Therapeutics (United States))
Cited by 21
Related Papers
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation
|American Journal of Kidney Diseases|2018|644
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Renal Transport of Uric Acid: Evolving Concepts and Uncertainties
|Advances in Chronic Kidney Disease|2012|394
Pathophysiologic basis for normouricosuric uric acid nephrolithiasis
|Kidney International|2002|346